AI health use is influencing care decisions and health product purchases. Structured pricing, availability, and eligibility data can help brands surface in AI results.
Lilly and Novo paid 250,000+ GLP-1 prescribers since 2018, more than any Rx class, showing how heavily pharma will invest in HCP marketing to differentiate brands.
Healthcare and pharma marketers can tailor AI-friendly content to questions about symptoms, side effects, treatments, and managing care.
It also hits on major pain points with daily insulin and gives drugmakers a new way to reach people delaying treatment.
Insurers say AI coding raises healthcare costs. Both hospitals and payers are using AI to protect margins, while systemwide savings remain elusive.
Healthcare providers still favor print for patient education, but patients value actionable digital resources they can revisit at home.
Consumer demand is notable even without insurance coverage, but wider use could add diagnostic work for providers.
Diagnostic delays and dismissed symptoms leave room for better care and patient tools.
56% of US GLP-1 users who are trading up to premium food and beverages say it's because they eat less overall, so they can afford higher-quality food, according to a November survey from The New Consumer and Coefficient Capital.
Expanded Medicare coverage has brought 700,000+ new users since July—tailored care and support will need to scale just as quickly.
ACA removals add fuel to the midterm healthcare debate, with voter perceptions hinging on whether coverage cancellations over alleged fraud prove accurate.
We attended Fierce Pharma Week, where speakers noted that AI insights that improve patient experiences and content are the next frontier.
Pharma B2B digital ad spend will jump 15% this year. Marketers can build consumer awareness and equip doctors with treatment information for patient conversations.
AI-driven drug research investments are surging, but results will take years. Pharma should measure progress at each R&D stage rather than promise near-term breakthroughs.
32% of working-age Americans with private insurance carry medical debt, with harmful financial and health consequences.
This increases the risk that misinformation could influence decisions about starting, changing, or stopping birth control.
While 70% plan to job hunt in the next year, clear advancement and education opportunities could help keep them.
Dedicated GLP-1 shelf space for digestive and pain relief products helped lift Haleon sales 24%, giving health and CPG brands with GLP-1-adjacent items a case to follow.
The broader shift in eating habits remains, but oral medications appear less disruptive than injections.
A PGA Tour pharma sponsorship connects its brand to an older, affluent audience with strong healthcare ties.